2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 755

Increased Degradation of BMPR2 in a TGFβ Dependent Transgenic Mouse Model of Scleroderma with Susceptibility to Pulmonary Arterial Hypertension
Abstract Number: 2939

Increased Diagnosis of Spondyloarthritis in Female Patients Started in the Early Biologic Era
Abstract Number: 748

Increased Expression of Chemerin in Endothelial Cells Due to Fli1 Deficiency May Contribute to the Development of Digital Ulcers in Systemic Sclerosis
Abstract Number: 1956

Increased IL-6 Production By Effector B Cells in Giant Cell Arteritis and Polymyalgia Rheumatica
Abstract Number: 2224

Increased Immune Complex Levels in Children with Juvenile Dermatomyositis Are Not Associated with Levels of Von Willebrand Factor Antigen, C4, Duration of Illness, Disease Activity Score, or the Absolute NK Count
Abstract Number: 355

Increased Left Ventricular Mass Index and Decreased Ejection Fraction Are Associated with Disease Activity in Rheumatoid Arthritis Patients without Cardiac Symptoms; Comparison Between Non-Biologic and Biologic Dmards Treatment Groups, Using a Cardiac Magnetic Resonance Imaging
Abstract Number: 783

Increased Migration and Proliferation Potential Characterize Vascular Smooth Muscle Cells from Patients with Giant Cell Arteritis
Abstract Number: 1804

Increased Mortality in Ankylosing Spondylitis – Results from a National Population Based Study
Abstract Number: 1713

Increased Number of CD206⁺cells in Peripheral Blood and Skin of Systemic Sclerosis Patients
Abstract Number: 1443

Increased Occurence of Carotid and Femoral Plaques, but Not Increased Arterial Stiffness of Hypertrophy, in Classical Risk Factor-Free Patients with Rheumatoid Arthritis
Abstract Number: 363

Increased Prevalence of Plasma Anti-Nuclear, Anti-SSA, and Connective Tissue Disease Associated Antibodies in African American Patients with Rheumatoid Arthritis
Abstract Number: 1770

Increased Risk of Chronic Obstructive Pulmonary Disease in Granulomatosis with Polyangiitis: A General Population-Based Study
Abstract Number: 2932

Increased Risk of Deep Vein Thrombosis and Pulmonary Embolism in Sjögren’s Syndrome: A General Population-Based Cohort Study
Abstract Number: 2664

Increased Risk of Hematological Malignancies in Children Born to Women with SLE
Abstract Number: 1865

Increased Risk of Myocardial Infarction and Cerebrovascular Accidents after Diagnosis of Granulomatosis with Polyangiitis: A General Population-Based Cohort Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].